New Developments in Incretin-Based Treatments for MASLD Using Single, Dual, or Triple Receptor Targets

Phase 2 clinical trials have shown histological improvements in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) with incretin-based therapies.

• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have progressed from phase 2 to phase 3 trials, focusing on the long-term efficacy of subcutaneous semaglutide.
• Newer agents combining glucose-dependent insulinotropic peptide and/or glucagon receptor agonist functions are also being investigated for their effects on MASLD/MASH.
• Evidence suggests that incretin receptor agonists may improve not only liver histology but also MASLD-related complications outside the liver.
• Incretin-based pharmacotherapies could be particularly beneficial for individuals with coexisting obesity or type 2 diabetes mellitus.
• There is a growing interest in understanding the hepatoprotective mechanisms of incretin-based treatments for MASLD and MASH.

Simplified